Business Description
Invex Therapeutics Ltd
ISIN : AU0000048621
Share Class Description:
ASX:IXC: Ordinary SharesDescription
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.93 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -10.9 | |||||
| 3-Year EPS without NRI Growth Rate | 9.8 | |||||
| 3-Year FCF Growth Rate | -14.5 | |||||
| 3-Year Book Growth Rate | -43.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.71 | |||||
| 9-Day RSI | 53.12 | |||||
| 14-Day RSI | 46.79 | |||||
| 6-1 Month Momentum % | 9.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.17 | |||||
| Quick Ratio | 14.17 | |||||
| Cash Ratio | 13.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 266.14 | |||||
| 5-Year Yield-on-Cost % | 266.14 | |||||
| Shareholder Yield % | 532.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.92 | |||||
| Price-to-Tangible-Book | 0.88 | |||||
| EV-to-EBIT | 0.23 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-FCF | 0.31 | |||||
| Price-to-Net-Current-Asset-Value | 0.88 | |||||
| Price-to-Net-Cash | 1 | |||||
| Earnings Yield (Greenblatt) % | 434.78 | |||||
| FCF Yield % | -46.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Invex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.022 | ||
| Beta | 0.94 | ||
| Volatility % | 47.93 | ||
| 14-Day RSI | 46.79 | ||
| 14-Day ATR (A$) | 0.001372 | ||
| 20-Day SMA (A$) | 0.0699 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (A$) | 0.06 - 0.105 | ||
| Shares Outstanding (Mil) | 75.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Invex Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Invex Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Invex Therapeutics Ltd Frequently Asked Questions
What is Invex Therapeutics Ltd(ASX:IXC)'s stock price today?
The current price of ASX:IXC is A$0.07. The 52 week high of ASX:IXC is A$0.11 and 52 week low is A$0.06.
When is next earnings date of Invex Therapeutics Ltd(ASX:IXC)?
The next earnings date of Invex Therapeutics Ltd(ASX:IXC) is .
Does Invex Therapeutics Ltd(ASX:IXC) pay dividends? If so, how much?
The Dividend Yield %  of Invex Therapeutics Ltd(ASX:IXC) is 266.14% (As of Today), Highest Dividend Payout Ratio of Invex Therapeutics Ltd(ASX:IXC) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Invex Therapeutics Ltd(ASX:IXC) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers